Q-omics provides the consensus-scored LRRC32 profile across patient tissues and cancer cell-line models. LRRC32 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LRRC32 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, LRRC32 protein abundance shows 22,684 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KICH, and LSCC as cancer lineages where LRRC32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC32 survival associations across molecular data types. LRRC32 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC32 RNA expression–survival associations across cancer types. High LRRC32 expression shows unfavorable associations in BLCA, MESO, THCA, STAD and KIRP, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LRRC32 RNA expression.
This table summarizes LRRC32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LRRC32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC32 shows lower tumor expression in KICH, LUAD, LUSC, UCEC and KIRP and higher tumor expression in HNSC. The KICH box plot shows higher LRRC32 RNA expression in normal versus tumor tissue (log2 FC = −2.692, t-test p < 0.001).
This table shows molecular features associated with LRRC32 in patient tissues and cancer cell lines. In patient samples, LRRC32 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
